Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pf-232798. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 12/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 8/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-232798 SCHEMBL14700573 | 1.00 | CCR5 (1.00) | CCR5KCNH2 | |
| Pf-232798 SCHEMBL30227242 | 1.00 | CCR5 (1.00) | CCR5KCNH2 | |
| Pf-232798 SCHEMBL1527455 | 1.00 | CCR5 (1.00) | CCR5KCNH2 | |
| Pf-232798 SCHEMBL3071187 | 0.96 | CCR5 (0.92) | CCR5KCNH2 | |
| Pf-232798 SCHEMBL3075843 | 0.96 | CCR5 (0.92) | CCR5KCNH2 | |
| Pf-232798 SCHEMBL3075846 | 0.96 | CCR5 (0.92) | CCR5KCNH2 | |
| SCHEMBL30227452 | 0.94 | CCR5 (0.89) | CCR5KCNH2 | |
| SCHEMBL3070604 | 0.94 | KCNH2 (1.00) | CCR5KCNH2 | |
| SCHEMBL3070606 | 0.94 | KCNH2 (1.00) | CCR5KCNH2 | |
| SCHEMBL2575130 | 0.93 | KCNH2 (0.90) | CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566670-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| EP-4403221-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| EP-2741777-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION | INSERM - INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2017-01-18 | — | — | EP | claimed |
| US-20140271680-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION | UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE (FR) | 2014-09-18 | — | — | US | claimed |
| US-20140057940-A1 | Methods for Treating or Preventing Cardiac and Neurological Disorders Using Chemokine Receptor Antagonists | MANKOWSKI JOSEPH L (US) | 2014-02-27 | — | — | US | claimed |
| EP-2552429-A1 | COMBINATION THERAPY COMPRISING A CCR5 ANTAGONIST, A HIV-1 PROTEASE INHIBITOR AND A PHARMACOKINETIC ENHANCER | Phivco-1 LLC (US) | 2013-02-06 | — | — | EP | claimed |
| US-20130023496-A1 | Combination Therapy Comprising A CCR5 Antagonist, A HIV-1 Protease Inhibtior and a Pharmacokinetic Enhancer | PHIVCO-1 LLC | 2013-01-24 | — | — | US | claimed |
| WO-2012097062-A1 | METHODS FOR TREATING OR PREVENTING CARDIAC AND NEUROLOGICAL DISORDERS USING CHEMOKINE RECEPTOR ANTAGONISTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-07-19 | — | — | WO | claimed |
| WO-2011121558-A1 | COMBINATION THERAPY COMPRISING A CCR5 ANTAGONIST, A HIV-1 PROTEASE INHIBITOR AND A PHARMACOKINETIC ENHANCER | PHIVCO-1 LLC (US) | 2011-10-06 | — | — | WO | claimed |
| US-20100267765-A1 | Pharmaceutical Compositions and Methods for CCR5 Antagonists | FELSTEAD STEPHEN JOHN | 2010-10-21 | — | — | US | claimed |
| US-7790740-B2 | Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation | PFIZER INC (US) | 2010-09-07 | — | — | US | claimed |
| EP-1937639-B1 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | claimed |
| EP-2043640-A2 | CCR5 ANTAGONIST FOR ENHANCING IMMUNE RECONSTITUTION AND TREATING OPPORTUNISTIC INFECTION IN HIV PATIENTS | Pfizer Products Inc. (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2007144720-A2 | CCR5 ANTAGONIST FOR ENHANCING IMMUNE RECONSTITUTION AND TREATING OPPORTUNISTIC INFECTION IN HIV PATIENTS | PFIZER PRODUCTS INC. (US) | 2007-12-21 | — | — | WO | claimed |
| US-7309790-B2 | Chemical compounds | PFIZER INC (US) | 2007-12-18 | — | — | US | claimed |
| EP-1682545-B1 | IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION | PFIZER LTD (GB) | 2007-12-12 | — | — | EP | claimed |
| US-20050131011-A1 | Chemical compounds | PFIZER, INC. | 2005-06-16 | — | — | US | claimed |
| US-20260109747-A1 | Conjugate Comprising an IL-2 Moiety | ASCENDIS PHARMA ONCOLOGY DIV A/S (DK) | 2026-04-23 | — | — | US | disclosed |
| WO-2006077499-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| US-20050131011-A1 | Chemical compounds | PFIZER, INC. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109747-A1 | Conjugate Comprising an IL-2 Moiety | IL2, IL2RA, ILF2 | CCR5 694/4885KCNH2 3144/4885 |
| US-20100267765-A1 | Pharmaceutical Compositions and Methods for CCR5 Antagonists | CETP, CCR5, MTTP | CCR5 2/4885KCNH2 4441/4885 |
| US-20050131011-A1 | Chemical compounds | CCR5, CCR2, CX3CR1 | CCR5 1/4885KCNH2 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.